Application of human ING4 gene serving as radiation sensitizer

Abstract

The invention discloses an application of a human ING4 gene serving as a tumor radiation sensitizer and also provides a method for enhancing the sensitivity of in-vivo / in-vitro tumor cells to radiation. The method comprises the following steps: introducing a human ING4 gene into the in-vivo / in-vitro tumor cells before radiation so as to enable the human ING4 gene to be expressed in the tumor cells, and then radiating the human tumor cells. According to the application of the human ING4 gene serving as the radiation sensitizer and the method for enhancing the sensitivity of in-vivo / in-vitro tumor cells to radiation, the ING4 gene can be applied to a tumor radiation process, thereby obviously promoting the sensitivity of different tumor cells to radiation, effectively restraining the growthof the tumor cells and inducing the tumor cells to die.

Description

technical field [0001] The invention relates to genomics, molecular biology, cell biology, genetic engineering and clinical medicine. The invention specifically relates to the application of human ING4 gene as a chemotherapeutic drug sensitizer. Background technique [0002] Radiation therapy is one of the routine means of tumor treatment, and 70% to 80% of malignant tumor patients need to receive radiotherapy during the course of treatment. Tumor insensitivity or resistance to radiation is one of the main reasons why radiation therapy is difficult to cure malignant tumors. In recent years, with the in-depth research on the molecular mechanism of tumor pathogenesis and the mechanism of cell growth regulation, some exciting results have been achieved in tumor gene therapy, but the transgene therapy targeting a single link often cannot achieve satisfactory therapeutic effects. Weichselbaum et al. proposed a new idea of ​​tumor gene-radiation therapy in 1994. The principle is ...

AI Technical Summary

Problems solved by technology

[0004] However, there is no report about the application of human ING4 gene as a tumor radiosensitizer, and those skilled in the art know that chemotherapy sensitizers may not be used as radiosensitizers; radiosensitization is mainly for intratumoral radioresistance. The part of hypoxic cells is proposed, which refers to certain chemical substances that can enhance the killing effect of radiation on hypoxic cells in tumors and cause less damage to oxygenated normal tissues. These chemical substances are called radiosensitizers. Commonly used radiosensitizers mainly include misonidazole (MISO), glycididazole sodium (CMNa), flavone acetic acid and oxygen; some drugs can be used as radiosensitizers and chemotherapy sensitizers, such as miso- Nitazole (MISO), glycidiazole sodium (CMNa), CMNa, cyclophosphamide, fluorouracil, VP-16, bleomycin, mitomycin C, (hydroxy)camptothecin, paclitaxel, doxorubicin , cis (carbo)platinum, etc.; but some drugs can only be used as chemotherapy sensitizers but not radiotherapy sensitizers, such as sulfonine, decitabine, etc., which can overcome drug resistance and make cancer better treated

[0005] Moreover, there are no literature reports about the human ING4 gene expression vector and its gene-encoded protein having radiosensitizing effects.

Images